Autolus Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AUTL and other ETFs, options, and stocks.

About AUTL

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. 

CEO
Christian Martin Itin
CEOChristian Martin Itin
Employees
752
Employees752
Headquarters
London, Greater London
HeadquartersLondon, Greater London
Founded
2018
Founded2018
Employees
752
Employees752

AUTL Key Statistics

Market cap
592.21M
Market cap592.21M
Price-Earnings ratio
-2.13
Price-Earnings ratio-2.13
Dividend yield
Dividend yield
Average volume
1.56M
Average volume1.56M
High today
$2.30
High today$2.30
Low today
$2.22
Low today$2.22
Open price
$2.29
Open price$2.29
Volume
1.84M
Volume1.84M
52 Week high
$2.58
52 Week high$2.58
52 Week low
$1.18
52 Week low$1.18

AUTL News

TipRanks 3d
Top Autolus Executive Makes Notable Move With Fresh Stock Sale

New insider activity at Autolus Therapeutics ( (AUTL) ) has taken place on September 3, 2026. U.S. Chief Commercial Officer and Country General Manager Cintia P...

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.